Seeking Alpha

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next ...

Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses ...
KRON4 News

Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T Pipeline Into the Clinic

Schoenefeld/Berlin, Germany, November 17, 2025 --- Captain T Cell, a biotechnology company developing next-generation TCR-T cell therapies for solid tumors, today announced the successful closing of ...
ascopubs.org

Identifying peripheral cancer-associated TCR signals for the early-detection of lung cancer.

Investigating the association of blood-to-tissue tumor mutation burden (TMB) ratio with overall survival and intratumor heterogeneity (ITH) in advanced NSCLC. This is an ASCO Meeting Abstract from the ...
Nasdaq

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next ...

IMA402 and IMA401 TCR Bispecifics showed favorable tolerability at RP2D as well as deep and durable responses in heavily pre-treated, last-line patients with a range of solid tumors IMA402 PRAME ...
Eagle-Tribune

Captain T Cell Closes Financing Round to Advance its Proprietary, Next-Generation TCR-T ...

Available funding totaling EUR 20 million dedicated to developing novel solid tumor treatments addressing a high unmet medical need Springboard Health Angels, Pluton Asset Holding AG, Sintra Limited, ...